Info

🌱 來自: Molecular biology-of-NSCLC

EGFR Mt

• 15% of ADCL,
• [exon 19 deletions] (45%),
• exon 21 L858R (40%),
• exon 18 (G719X),
• exon 20 (S768I),
• exon 21 (L861Q),
• confer EGFR TKI Sn,
• initially described in never-smokers,
• but also present in pts w/ smoking histories (JCO 2011;29:2066).
• Exon 20 insertions now targetable driver.
• Acquired T790M Mt confers resistance to earlier generation EGFR TKIs (NEJM 2005;352:786)

Backlink

• management of Stage IV metastatic disease of NSCLC
• management of Pathologic stage I to IIIA NSCLC
• Pathologic stage I to IIIA (N1) of NSCLC Treatment
• Molecular biology-of-NSCLC
• Targeted therapy-of-NSCLC